Newcelx Ltd. current report, Q4 FY2022

Vollständiges Dokument

Business Context and Reporting Period

This Form 6-K was furnished by NLS Pharmaceutics Ltd., a Swiss pharmaceutical company, for October 2022 and signed on October 3, 2022. The filing concerns a proposed private placement, conversion of existing short-term notes, and a Nasdaq delisting determination. The request metadata identifies Newcelx Ltd., but the filing itself identifies NLS Pharmaceutics Ltd.

Key Financial and Capital Markets Metrics

  • Private placement: 5,194,802 common shares at $0.77 per share, together with warrants to purchase up to 2,597,401 shares at an exercise price of $0.70 per share.
  • Expected gross proceeds: Approximately $4.0 million, before expenses and a placement fee equal to 3.5% of gross proceeds.
  • Warrant terms: Common warrants are immediately exercisable and expire five years after issuance.
  • Note conversion: Existing short-term notes with $1.53 million of principal, plus accrued interest, are expected to convert into 2,516,429 common shares and warrants to purchase up to 1,258,215 shares at $0.70 per share.
  • Use of proceeds: Development of Quilience (Mazindol ER) for narcolepsy, business development and licensing activities, and general corporate purposes.
  • Liquidity and profitability: The filing does not provide revenue, net income, cash flow, cash balance, margins, or a clear post-transaction liquidity runway.

Material Changes Versus the Prior Comparable Period

  • The company entered into the securities purchase agreement effective September 30, 2022, with the offering expected to close on or about October 7, 2022, subject to customary conditions.
  • Existing short-term notes issued in August 2022 are expected to be converted into equity and warrants rather than remain outstanding as debt.
  • Company insiders agreed to participate: Chairman Ronald Hafner agreed to purchase 324,675 shares, and Chief Medical Officer George Apostol agreed to purchase 1,298,701 shares.
  • The transaction will substantially increase shares outstanding and create additional potential dilution from the warrants. The filing does not state the pre-transaction share count.
  • The company intends to seek shareholder approval to increase its authorized share capital, which is required to permit exercise of warrants issued to the note holders.

Guidance, Outlook, Risks, Contingencies, and Unusual Items

  • Nasdaq compliance: Nasdaq notified the company on September 29, 2022 that it had failed to regain compliance with the $2.5 million minimum stockholders’ equity requirement under Listing Rule 5550(b)(1). Nasdaq staff initiated delisting procedures for the company’s common shares and warrants.
  • Appeal: The company intends to request a hearing to appeal the delisting determination. The filing does not state the likely outcome or whether a hearing would stay delisting.
  • Financing conditions: Closing of the private placement remains subject to customary closing conditions and applicable-law requirements.
  • Registration: The company agreed to file an SEC registration statement covering resale of the securities within 60 days after closing.
  • Share issuance restrictions: The company agreed not to issue or announce proposed issuances of common shares or equivalents for 30 days following closing, subject to exceptions.
  • Warrant exercise limitation: Purchasers holding warrants for approximately 1.0 million shares may agree not to exercise them until authorized share capital is increased.
  • Offering exemptions: The securities were offered in reliance on Section 4(a)(2) and Rule 506(b) of Regulation D and were not registered under the Securities Act or applicable state securities laws.

Important Facts for Investors to Verify

  1. Whether the private placement closed as expected and the actual net proceeds received after fees and expenses.
  2. The company’s updated cash balance, burn rate, outstanding liabilities, and liquidity runway following the financing and note conversion.
  3. The fully diluted share count, including all shares issued in the financing and upon note conversion and all related warrants.
  4. Whether shareholders approved the proposed increase in authorized share capital and whether the warrants can be exercised.
  5. The status and outcome of the Nasdaq delisting appeal and the continued trading status of the common shares and warrants.
  6. The development, regulatory, financing, and commercialization prospects for Quilience (Mazindol ER).